Karyopharm Therapeutics (KPTI) Expected to Release Earnings on Monday

Posted by Stanley Muller on Aug 3rd, 2026

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) is expected to announce its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Karyopharm Therapeutics to announce earnings of ($1.37) per share and revenue of $33.12 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.21. The company had revenue of $35.07 million during the quarter, compared to analyst estimates of $31.40 million. On average, analysts expect Karyopharm Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Karyopharm Therapeutics Trading Up 0.3%

NASDAQ KPTI traded up $0.01 on Monday, reaching $1.93. 1,429,855 shares of the company were exchanged, compared to its average volume of 890,317. The business’s fifty day moving average price is $8.88 and its 200 day moving average price is $8.19. The stock has a market capitalization of $43.62 million, a P/E ratio of -0.13 and a beta of 0.90. Karyopharm Therapeutics has a fifty-two week low of $1.80 and a fifty-two week high of $10.99.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds have recently made changes to their positions in the business. State Street Corp lifted its holdings in Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after buying an additional 12,600 shares in the last quarter. Royal Bank of Canada grew its stake in Karyopharm Therapeutics by 761.3% during the 4th quarter. Royal Bank of Canada now owns 58,000 shares of the company’s stock worth $427,000 after purchasing an additional 51,266 shares in the last quarter. Jump Financial LLC acquired a new stake in Karyopharm Therapeutics in the 4th quarter valued at about $396,000. ADAR1 Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics by 100.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock valued at $368,000 after buying an additional 25,000 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $307,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Robert W. Baird lowered Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Friday. Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Finally, HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Get Our Latest Research Report on KPTI

About Karyopharm Therapeutics

(Get Free Report)

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.